Clinical trials: Germ Cell Cancer
Melanoma (Skin), Moles Multiple Benign
MoleGazer Development Feasibility Study
Melanoma (skin cancer) frequently develops from existing moles on the skin. Current practice relies on expert dermatologists being able to successfully identify new/changing moles in individuals with multiple moles.
- Trial name
- NCT05015816
- Testing
- Total body photography
- Where
- United Kingdom
- Volunteers
- 374 people, healthy volunteers welcome
- Sponsor
- Oxford University Hospitals NHS Trust
Breast Cancer, Lung Cancer
Study for the Multidimensional Analyses of Resistance and Toxicity to Immune- and Targeted-therapies.
Novel treatment modalities like targeted therapies and Immune checkpoint inhibitors have revolutionised the therapeutic landscape in oncology and hematology, significantly improving outcomes even in clinical contexts in which…
- Conditions
- Breast Cancer, Lung Cancer, Melanoma, Head and Neck Cancer
- Trial name
- POSITive (NCT06321640)
- Testing
- Cohort A: primarily operable disease, candidate to adjuvant, Cohort B: locally advanced disease, Cohort C: metastatic disease
- Where
- Italy
- Volunteers
- 265 people, healthy volunteers welcome
- Sponsor
- European Institute of Oncology
Melanoma
Moletest Clinical Study in Scotland
To evaluate an iPad based photoimage analysis system (Moletest) for improving discrimination of benign from malignant suspicious skin lesions or moles.
- Trial name
- NCT02196246
- Where
- United Kingdom
- Volunteers
- 1,120 people, healthy volunteers welcome
- Sponsor
- Moletest Scotland Ltd
Neuroendocrine Tumor
Gastrointestinal Motility in Patients With Neuroendocrine Tumors
We will study the total gastrointestinal transit time (GITT), gastric emptying and small intestine motility in NET patients before and after treated with somatostatin analogues and compare these to healthy subjects.
- Trial name
- NCT00789841
- Testing
- Magnetic Tracking System (MTS) and radio-opaque markers
- Where
- Denmark
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- University of Aarhus
Autonomic Nervous System Disease, Healthy
Blood Sampling for Neurochemical and Genetic Testing
This study involves sampling blood from both normal volunteers and patients with diseases known or suspected to involve body chemicals called catecholamines.
- Conditions
- Autonomic Nervous System Disease, Healthy, Hypertension, Pheochromocytoma
- Trial name
- NCT00001147
- Where
- United States
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Glioma
MR Based Prediction of Molecular Pathology in Glioma Using Artificial Intelligence
This registry aims to collect clinical, molecular and radiologic data including detailed clinical parameters, molecular pathology (1p/19q co-deletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new…
- Trial name
- NCT04217018
- Testing
- Prediction of molecular pathology
- Where
- China
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Breast Cancer, Non-Small-Cell Lung Cancer
Biodistribution and Safety of the PET Probes [18F]FPRGD2 and [18F]FPPRGD2
The purpose of the study was to conduct a pilot test of new tracers ([18F]FPRGD2 and [18F]FPPRGD2) to define normal tracer biodistribution (where the tracer goes), stability (how much metabolises), pharmacokinetics (how much…
- Conditions
- Breast Cancer, Non-Small-Cell Lung Cancer, Glioblastoma, Other Cancers
- Trial name
- NCT01383135
- Testing
- F18-FPPRGD2
- Where
- United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- Stanford University
Melanoma, Renal Cancer
Microbiome Immunotherapy Toxicity and Response Evaluation
This is a observational study to investigate how the microbiome correlates with efficacy and toxicity of immune checkpoint inhibitors in patients with advanced cancer.
- Conditions
- Melanoma, Renal Cancer, Lung Cancer
- Trial name
- NCT04107168
- Testing
- Nivolumab, Pembrolizumab, Ipilimumab
- Where
- 13 sites in United Kingdom
- Volunteers
- 1,800 people, healthy volunteers welcome
- Sponsor
- CCTU- Cancer Theme
Neuroendocrine Tumors
The Indol Profile; Exploring the Metabolic Profile of Neuroendocrine Tumors
This is an observational and exploratory study. Participants will be asked for a blood collection and a 24- hour collection of urine.
- Trial name
- NCT02815969
- Testing
- vena punction
- Where
- Netherlands
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- University Medical Center Groningen
Melanoma (Skin Cancer), Artificial Intelligence (AI)
Artificial Intelligence Based Melanoma Early Diagnosis and Risk Prediction in Children, Adolescents and Young Adults
The goal of this study is to develop supportive diagnostic artificial intelligence algorithms to distinguish melanoma from nevi or other benign pigmented skin lesions, especially in younger patients (below the age of 30).
- Conditions
- Melanoma (Skin Cancer), Artificial Intelligence (AI), Pediatric Cancer
- Trial name
- AI-MEL (NCT06621810)
- Where
- 3 sites in Germany, Italy and 1 more
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- German Cancer Research Center
Malignant Melanoma, Nevus, Pigmented
Fast Track Diagnosis of Skin Cancer by Advanced Imaging
Aim of study: To collect data for a new image-guided diagnostic algoritm, enabling the investigators to differentiate more precisely between benign and malignant pigmented tumours at the bedside.
- Conditions
- Malignant Melanoma, Nevus, Pigmented, Basal Cell Carcinoma, Seborrheic Keratosis
- Trial name
- NCT04229277
- Testing
- optical coherence tomography
- Where
- Denmark
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- University Hospital Bispebjerg and Frederiksberg
Dementia, Movement Disorders
Comparison of NeuroEXPLORER PET/CT Versus Standard-of-care PET/CT of the Head and Neck Region.
The goal of this clinical study is to compare the current standard-of-care PET/CT scanner with the new NeuroEXPLORER PET/CT, with the aim of demonstrating the added diagnostic value of the new scanner.
- Conditions
- Dementia, Movement Disorders, ALS - Amyotrophic Lateral Sclerosis, Epilepsy
- Trial name
- NCT07595666
- Testing
- Standard-of-care PET/CT, NeuroEXPLORER
- Where
- Belgium
- Volunteers
- 1,600 people, healthy volunteers welcome
- Sponsor
- prof. dr. Koen Van Laere
Spinal Muscular Atrophy, Fragile X Syndrome
Early Check: Expanded Screening in Newborns
Early Check provides voluntary screening of newborns for a selected panel of conditions. The study has three main objectives: 1) develop and implement an approach to identify affected infants, 2) address the impact on infants and…
- Conditions
- Spinal Muscular Atrophy, Fragile X Syndrome, Fragile X - Premutation, Duchenne Muscular Dystrophy
- Trial name
- NCT03655223
- Testing
- Confirmatory Testing
- Where
- United States
- Volunteers
- 30,000 people, healthy volunteers welcome
- Sponsor
- RTI International
Malignant Melanoma
SciBase International Melanoma Pivotal Study
The purpose of this clinical investigation was to determine the safety and effectiveness of the SciBase III device (Test) designed to help distinguish between malignant melanoma and benign lesions, using electrical impedance…
- Trial name
- NCT01077050
- Testing
- SciBase III Electrical Impedance Spectrometer
- Where
- 2 sites in United States, Sweden
- Volunteers
- 1,951 people, healthy volunteers welcome
- Sponsor
- SciBase AB
Melanoma, Gastrointestinal Cancer
Harvesting Cells for Experimental Cancer Treatments
Background: The NCI Surgery Branch has developed experimental therapies that involve taking white blood cells from patients' tumor or from their blood, growing them in the laboratory in large numbers, and then giving the cells…
- Conditions
- Melanoma, Gastrointestinal Cancer, Metastatic Cancer, Breast Cancer
- Trial name
- NCT00068003
- Testing
- Anti-CD19 CAR PBL
- Where
- United States
- Volunteers
- 7,000 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Melanoma, BRAF V600 Mutation
Relative Bioavailability of Binimetinib 3 x 15 mg and 45 mg Formulations
The current commercially available MEKTOVI® (binimetinib) 15 mg tablets are provided as immediate release film-coated tablets for oral administration.
- Conditions
- Melanoma, BRAF V600 Mutation, Unresectable Melanoma, Metastatic Melanoma
- Trial name
- NCT05103891
- Testing
- Binimetinib Oral Tablet
- Where
- France
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Melanoma
Long Term Quality of Life in Melanoma Patients in Netherlands
Study of late physical, psychological and social effects in patients treated with ipilimumab for advanced (stage IV or unresectable stage III) melanoma.
- Trial name
- NCT03450876
- Testing
- Non-Interventional
- Where
- Netherlands
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Cardiovascular Abnormalities, Arterial Blood Pressure
Multicenter Study on Cardiovascular and Metabolic Complications in Patients With Biochemically Silent Pheochromocytomas and Paragangliomas
The aim of the study is to characterise the cardiovascular and metabolic complications pre- and post-surgery of patients with biochemically negative PPGL and to compare them with normal individuals and patients with secreting…
- Conditions
- Cardiovascular Abnormalities, Arterial Blood Pressure, Heart Rate, Congestive Heart Failure Chronic
- Trial name
- NCT07316075
- Where
- Greece
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Laikο General Hospital, Athens
Pancreas Neoplasm, Neuroendocrine Tumors
Portal Vein Resection in Pancreatic Neuroendocrine Tumours
The limited evidence on the value of portal vein resection in patients with borderline resectable and/or locally advanced PanNENs is an incentive to carry out a retrospective multicentre study amongst centres with specific…
- Trial name
- PVNET (NCT04336839)
- Testing
- Portal vein resection / reconstruction
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Royal Free Hospital NHS Foundation Trust
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion
The goal of this study is to determine the response of the study drug loratinib in treating children who are newly diagnosed high-grade glioma with a fusion in ALK or ROS1.
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Infant Type Hemispheric Glioma
- Trial name
- NCT06333899
- Testing
- Lorlatinib, Lorlatinib with chemotherapy1, Lorlatinib with chemotherapy 2
- Where
- 18 sites in United States, Australia and 4 more
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- Nationwide Children's Hospital